2025
Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.
Riaz F, Vaughn J, Zhu H, Dickerson J, Sayegh H, Brongiel S, Baldwin E, Kier M, Zaemes J, Hearn C, Abdelghany O, Cohen R, Parikh R, Reuss J, Prsic E, Doroshow D. Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis. JCO Oncology Practice 2025, op2400788. PMID: 39937997, DOI: 10.1200/op-24-00788.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsOverall survivalICI administrationSolid malignanciesPatients treated with immune checkpoint inhibitorsAdministration of immune checkpoint inhibitorsMultivariate Cox proportional hazards model analysisResponse to ICI therapyCox proportional hazards model analysisProportional hazards model analysisAdvanced solid malignanciesKaplan-Meier methodOutcomes of patientsInstitutional electronic medical recordsHazards model analysisCox proportional hazards modelsProportional hazards modelCheckpoint inhibitorsICI therapyMedian OSICI initiationICI useRetrospective studyClinical outcomesClinicodemographic variables
2024
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.Peer-Reviewed Original ResearchNon-small cell lung cancerEnd of lifeMonth of deathImmunotherapy initiationCohort studyMAIN OUTCOMEStage IV non-small cell lung cancerCharlson-Deyo comorbidity indexHigh metastatic burdenInitiation of immunotherapyNational prescribing patternsRisk-adjusted patientsImmune checkpoint inhibitorsRetrospective cohort studyStage IV melanomaPercentage of patientsHigh-volume centersLocation of metastasesLow-volume centersOdds of deathCell lung cancerNational Clinical DatabaseLow-volume facilitiesDrug Administration approvalCheckpoint inhibitors
2022
The Inpatient Immunotherapy Outcomes study: A multicenter retrospective study of patients treated with immune checkpoint inhibitors in the inpatient setting.
Riaz F, Zhu H, Cheng W, Brongiel S, Baldwin E, Kier M, Zaemes J, Hearn C, Abdelghany O, Parikh R, Reuss J, Prsic E, Doroshow D. The Inpatient Immunotherapy Outcomes study: A multicenter retrospective study of patients treated with immune checkpoint inhibitors in the inpatient setting. Journal Of Clinical Oncology 2022, 40: 300-300. DOI: 10.1200/jco.2022.40.28_suppl.300.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsICI therapyCheckpoint inhibitorsRetrospective studyInpatient settingOutcome studiesPT outcomesStage IV solid malignancyYale-New Haven HospitalImaging-based responseMedian prior linesNon-curative intentOutcome of ptsCTLA-4 inhibitorsMulticenter retrospective studyPD-L1 expressionPoor clinical outcomeCare of patientsTime of administrationMount Sinai HospitalGeorgetown University HospitalHealth care systemICI administrationICI doseICI initiation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply